Mechanistic insights in mitral valve prolapse and associated left ventricular remodelling: Barlow*s Disease versus Fibroelastic Deficiency

Mechanistic insights in mitral valve prolapse and associated left ventricular remodelling: Barlow*s Disease versus Fibroelastic Deficiency - Mitral valve prolapse and left ventricular remodelling

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON52184

Enrollment

100

Registered

2023-01-17

Start date

2024-03-01

Completion date

Unknown

Last updated

2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bulging mitral valve mitral valve prolapse

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: * Non syndromal mitral valve prolapse * Age 18-80 years old * Legally and mentally competent to sign informed consent

Exclusion criteria

Exclusion criteria: * History of cardiac surgery * Concomitant valve disease (moderate - severe) * Ischaemic heart disease * Hypertrophic cardiomyopathy * Intra-cardiac device * History of myocarditis * Left bundle branch block * Chronic kidney disease stage 4-5 * Pregnancy

Design outcomes

Primary

Measure	Time frame
Difference in left ventricular volume and function, prolapse volume and mitral regurgitant volume in patients with Barlow's Disease versus Fibroelastic Deficiency, measured by echocardiography and cardiac magnetic resonance imaging.	—

Secondary

Measure	Time frame
1) Difference in genetic variants (incl. cardiomyopathy and mitral valve prolapse genes genes) in patients with Barlow's Disease versus Fibroelastic Deficiency 2) Difference in ventricular arrhythmias (incl. ventricular ectopy, (non)sustained ventricular tachycardia, ventricular fibrillation and sudden cardiac death) in patients with Barlow's Disease versus Fibroelastic Deficiency and association with left ventricular fibrosis (detected by cardiac magnetic resonance late gadolinium enhancement)	—

Measure

Time frame

1) Difference in genetic variants (incl. cardiomyopathy and mitral valve prolapse genes genes) in patients with Barlow's Disease versus Fibroelastic Deficiency 2) Difference in ventricular arrhythmias (incl. ventricular ectopy, (non)sustained ventricular tachycardia, ventricular fibrillation and sudden cardiac death) in patients with Barlow's Disease versus Fibroelastic Deficiency and association with left ventricular fibrosis (detected by cardiac magnetic resonance late gadolinium enhancement)

—

Countries

Netherlands

Outcome results